Skip to main content
. Author manuscript; available in PMC: 2015 Jun 1.
Published in final edited form as: J Invest Dermatol. 2014 Jul 19;134(12):2908–2917. doi: 10.1038/jid.2014.263

Figure 1. IL-17 levels and MMP-9 activity are positively related in blister fluid before and after topical steroid treatment in BP patients.

Figure 1

(a) Scatter plots of the IL-17 levels measured by ELISA in control (CTR) serum, BP serum and BF collected at time of diagnosis. The solid line represents the mean level of IL-17 in each group. (b) MMP-9 activity was measured in healthy serum, BP serum and BF by gelatin zymography and ImageJ software was used for quantification. The error bars denote the mean± SD and Mann-Whitney test was used for statistics. (c) Blister number, MMP-9 activity, IL-17, BP180 and BP230 autoantibodies levels in BF were followed before and few days after the beginning of the treatment in 3 BP patients.